Category Archives: Glucose Monitoring

Amgen and Dexcom Q1 ’26 Earnings; Zealand to Elect Camilla Sylvest to Board; Esperion Gets Acquired; Senseonics Announces $80M Public Offering; Ozempic Pill Launches in US

A series of cardiometabolic-related news items has been observed from Amgen, Dexcom, Zealand Pharma, Esperion Therapeutics, Senseonics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Ascletis Completes Ph2 Enrollment for ASC30 in T2DM; GSK’s Efimosfermin Breakthrough Therapy and PRIME Designations; Tandem Control-IQ+ Pregnancy Indication; Tandem Mobi Correction; Sagimet Business Updates and Stock Pricing

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, GSK, Tandem Diabetes, and Sagimet Biosciences. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Additional Foundayo Prescription Trends; Regeneron MFN Deal; Arrowhead Positive CHMP Opinion; Eversense 365 CGM Launches in EU

A series of cardiometabolic-related news items has been observed from Lilly, Regeneron, Arrowhead Pharmaceuticals, and Senseonics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Pfizer’s Andrew Baum to Depart at the End of 2026; Amazon Launches AOM Management Program; Dexcom Opens First OUS CGM Manufacturing Site; Kailera Closes IPO; BioAge Reports Additional Ph1 NLRP3i Data; Abbott Wins Preliminary Injunction Appeal Against Sinocare

A series of cardiometabolic-related news items has been observed from Pfizer, Amazon, Dexcom, Kailera Therapeutics, BioAge Labs, and Abbott. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Early Foundayo Prescription Trends; Kailera Announces IPO Pricing; AZ’s Partner Initiates Ph1 FIH Study of Monthly Dual Agonist; ViCentra Eliminates Waiting Period for Kailedo Patch Pump in Select EU Countries

A series of cardiometabolic-related news items has been observed from Lilly, Kailera Therapeutics, AstraZeneca/CSPC Pharmaceuticals, and ViCentra. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Shares ACHIEVE-4 Topline Data and Receives CNPV for Orforglipron in T2DM; Novo Initiates AMAZE 2; Pfizer and D&D Pharmatech Research Service Agreement; Abbott Q1 ’26 Earnings; Novartis Ph1 HF Study

A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Pfizer, Abbott, and Novartis. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

ATTD 2026 Key Press Releases (March 13)

On the third day of ATTD 2026, four cardiometabolic-related news items have been observed from Insulet, TIXiMED, Biocon, and Sana Biotechnology. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here

ATTD 2026 Key Press Releases (March 11)

On the first day of ATTD 2026, four cardiometabolic-related news items have been observed from Skye Bioscience, Lilly, MiniMed, and LifeScan. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Kailera Initiates Another Ph2 Ribupatide Study; Ascletis Reports Topline Ph2 Data; Laekna Announces Topline Ph1 Data; Glooko Connects with Roche’s CGM; SK pharmteco to Manufacture Long-Acting API for Current Lilly Product; Novo Acknowledges FDA Form 483

A series of cardiometabolic-related news items has been observed from Kailera, Ascletis Pharma, Laekna, Glooko, SK pharmteco, and Novo Nordisk. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo and Hims Take Another Turn at a Partnership; AbbVie Reports Topline Ph1 Amylin Data; Regeneron & Hansoh Share Ph3 Olatorepatide China Results; Lilly Releases Statement on CMS Obesity BALANCE Model; Zepbound KwikPen Available on Amazon; Veru Enrolls First Patient in Ph2b PLATEAU Study; Sequel Expands AID Launch

A series of cardiometabolic-related news items has been observed from Novo Nordisk/Hims & Hers, AbbVie, Regeneron Pharmaceuticals/Hansoh, Lilly, Amazon, Veru, and Sequel Med Tech. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here